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ABSTRACT
Introduction: Chronic kidney disease (CKD) and osteoporosis are important health problems. There is an inter-
relationship between osteoporosis and CKD. Bone densitometry is the “gold” standard in the diagnosis of
osteoporosis. Unfortunately, there are some problems with the interpretation of bone densitometry in CKD
patients. The goal of this study was to determine bone mineral density (BMD) in CKD patients, to assess the
difference between genders and different sites of bone densitometry correlation between BMD and laboratory
parameters, and to assess the most optimal measuring site. Methods: We studied 134 hemodialysis (HD)
patients (62 females, 72 males). The mean age was 56.4 ± 12.4 years and the mean duration of HD was 54.4 ± 60
months. BMD of the lumbar spine (posterior–anterior projection and lateral projection), hip (femoral neck,
trochanter, intertrochanter, total femur, the Ward’s Triangle), and forearm (ultradistal (UD), middistal (MID), dis-
tal third portion, and total forearm) was measured using dual X-ray absorptiometry (DXA) (Hologic Delphi
apparatus). Values were expressed as BMD, T-score, and Z-score. Results: Females had lower values of BMD
in all measurement points. There were no significant differences in T- and Z-scores of forearm between males
and females. Age was in a positive correlation with lumbar spine BMD in males and females. There was a neg-
ative correlation with neck and forearm BMD in both groups. Serum parathyroid hormone (PTH) was also in
negative correlation with hip and forearm BMD in both groups. The best correlation of BMD in different sites
was between forearm and neck. Conclusion: BMD data in CKD patients should be interpreted with caution
and appendicular skeletal sites should be included in the evaluation.
Keywords: bone mineral density; dual X-ray absorptiometry; chronic kidney disease; hemodialysis; 
osteoporosis
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INTRODUCTION
Chronic kidney disease (CKD) and osteoporosis are
among the most significant health problems in the
developed world.1,2 Osteoporosis, generally defined
as a bone disorder characterized by an increased risk
of fracture, is the most commonly diagnosed bone
disease.3
The diagnosis of osteoporosis is based on bone
mineral density (BMD) criteria, established 15 years
ago by the World Health Organization (WHO). It is
most often assessed by dual X-ray absorptiometry
(DXA). Indeed, the WHO criteria for the diagnosis of
osteoporosis are only for DXA. Results are expressed
as BMD (g/cm2) or T- and Z-scores. The T-score is
the number of SDs from the mean of a healthy young
adult population. The Z-score is the number of SD
from the mean of a healthy age and gender-matched
population.3,4 The T-score is the “gold” standard in
defining osteoporosis. WHO criteria for the diagnosis
of osteoporosis are only the T-score, while the Z-score
could provide useful information in patients with sec-
ondary, that is, not age-related osteoporosis. The most
common skeletal sites measured by DXA are the lum-
bar spine and the proximal femur. Peripheral sites,
that is, the forearm, may also be measured. In the gen-
eral population, the risk of fracture increases as the
T-score goes down, approximately 2.5 times with each
1 SD decrease in bone mass.3,5
Bone disease, that is, renal bone disease, is one of
the most significant complications of CKD. There is
higher risk of developing fractures among CKD
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patients compared to the general population.6,7 Bone
turnover is extremely varied in CKD patients, from
high to low turnover, depending on the parathyroid
hormone (PTH) level.8 The differing effects of PTH
on cortical and trabecular bone are well known, that is,
excess PTH has catabolic effects on cortical and ana-
bolic effects on trabecular bone.9 Therefore, caution is
required in CKD patients when assessing a reduction
in bone mass by any of the densitometric methods.
Indeed, because of the different changes in bone
reduction rate and the different pathogenesis of bone
loss, it is difficult to apply WHO criteria in renal bone
disease.10 At this moment, we do not have a standard
method to evaluate bone loss in CKD patients and we
have not yet decided upon the optimal measurement
site (axial or appendicular).8,10 Furthermore, there are
differences in expressing DXA results (BMD, T-, or
Z-score) when evaluating bone loss in renal bone
disease.4,10
The goal of this study is to determine BMD at spec-
ified measurement points using the DXA method to
ascertain the difference between genders, to determine
a correlation in measurement points on the skeleton,
and to try to locate the most optimal site for measuring
BMD in dialysis patients. The aim of this study is also
to investigate the prevalence of osteopenia and
osteoporosis by using different criteria.
SUBJECTS AND METHODS
Patients
Overall, 134 patients, 62 females and 72 males, on
maintenance hemodialysis (HD) were included in a
cross-sectional study after obtaining their informed
consent. All patients were from a single dialysis center.
The mean age was 56.4 ± 12.4 years and the mean
duration of HD treatment was 54.0 ± 60.9 months. All
of the patients were on bicarbonate dialysis with a cal-
cium concentration of 1.5 mmol/L for 12–15 hours
per week for the last 5 years with hollow-fiber dia-
lyzers with a polysulfone membrane. Blood flow was
300–500 mL/min, and the flow of the dialysate was
500 mL/min. The water for dialysis was prepared by
the reverse osmosis method. Its conductivity was
below 10 μs/cm3. All of the patients in therapy had
been treated with phosphate binders (calcium carbon-
ate, sevelamer hydrochloride). Aluminum hydroxide
has not been used as a phosphate binder in our
patients for more than 20 years. We also used an active
form of vitamin D3 (calcitriol) in a daily dose between
0.25 and 0.5 μg, according to the clinical recommen-
dations for patients being treated by HD [Kidney
Disease Outcomes Quality Initiative (K/DOQI)].
Patients were not treated with estrogens, calcitonin,
bisphosphonates, teriparatide, or androgens. Patients
on dialysis for less than 6 months and patients who
had taken corticosteroids or who had a parathyroidec-
tomy were excluded from the study. All females were
postmenopausal or permanently amenorrheic. Two
patients had a hip fracture and one had a fracture of a
metatarsal bone in their medical histories. The preva-
lence of vertebral fractures was not studied.
The etiology of renal failure was glomerulonephritis
in 48 patients (36%), hypertensive nephropathy in
13%, pyelonephritis in 9%, tubulointerstitial nephritis
in 8%, diabetic nephropathy in only 8%, polycystic
kidney in 7%, other renal disease in 16%, and
unknown in 3%.
Bone mineral density
BMD was assessed by DXA using a Hologic apparatus
model Delphi W (S/N 70616). It was performed by
trained technicians. Daily calibration was used to
maintain the manufacturer’s precision standards. We
measured BMD at the following sites: the lumbar
spine, the hip, and the forearm. The lumbar spine was
measured in posterior–anterior (PA at L1–L4) projec-
tion and lateral–lateral (LL at L2–L3) projection. The
hip was measured in the area of the neck, the tro-
chanter (Troch), the intertrochanter (Inter), the total
hip, and the Ward’s Triangle (Ward’s). The forearm,
that is, radius of the nondominant side, was measured in
its ultradistal (UD) part, the middistal (MID) forearm,
one-third, that is, 33% forearm (1/3), and the total
forearm. The results are expressed as BMD (g/cm2)
and as a T-score and a Z-score. The T-score and the
Z-score in the area of the lumbar spine in the lateral
direction were not counted for men. According to the
WHO, osteoporosis is defined as a T-score < −2.5 and
low bone mass, or osteopenia, as it was previously
known, as a T-score from −1 to −2.5. The Interna-
tional Society for Clinical Densitometry (ISCD) rec-
ommends BMD measurement of the posteroanterior
lumbar spine (L1–L4) and hip (total and neck). The
lateral spine should not be used for diagnosing
osteoporosis, but it may have a role in monitoring. In
certain circumstances, the 33% radius (one-third
radius) of the nondominant forearm may be used for
diagnosis. Z-score patients were grouped as below the
expected range for age (Z-score < −2, proposed by the
ISCD) or low bone mass (Z-score < −1, as proposed
by the Osteoporosis Work Group).4,10
Biochemistry
The concentrations of calcium, phosphate, and alka-
line phosphatase (ALP) were measured by standard
biochemical methods and the product of calcium and
phosphate was calculated. Plasma PTH was measured
by a commercial chemiluminescence method for intact
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PTH (chemiluminescence method: Diagnostic Prod-
ucts Corp., Los Angeles, California, USA), and the
range of normal value was between 1.1 and 7.3 pmol/L.
Statistical analyses
Continuous data are expressed as a mean ± SD.
Comparisons between the two groups were made by
the T-test. Correlation was determined by Pearson’s
correlation coefficient. Statistical significance was
defined as p < 0.05.
RESULTS
Demographic and biochemical data
There was no difference in age between females and
males. Female patients were on HD for a longer time,
but the difference was not statistically significant.
PTH levels were significantly lower in male patients
(PTH 57.3 vs. 79.8 pmol/L, p = 0.02) as were ALP
levels (83.4 vs. 116.9 U/L, p = 0.02). There was no
statistically significant difference in the other labora-
tory parameters (Table 1).
Bone densitometric data
The results show that female patients had lower BMD
in all measured sites, as expected. In both groups, the
highest value of BMD was in the area of the intertro-
chanter and the lumbar spine (PA) (Table 2).
The lowest values for the T-scores in females
were at the lumbar spine LL (−3.1 ± 1.3) and at
MID forearm (−2.3 ± 1.9), and for males at UD
forearm (−1.6 ± 1.4). In both the groups, the lowest
values for the Z-scores were at the UD forearm, for
females −1.0 ± 1.5 and for males −0.9 ± 1.5 (Table 2).
The mean T-score at the hip was significantly lower
in female patients; however, there was no significant
difference of the T-score at the appendicular part of
skeleton, that is, forearm, other than significant dif-
ferences at MID forearm (−2.3 ± 1.9 vs. −1.4 ± 1.7,
p = 0.01). At the hip there was also a significant differ-
ence in Z-scores, whereas there was no difference in
Z-score at the forearm (Table 2).
Correlation between BMD and laboratory and 
clinical parameters
In male patients, BMD was correlated positively with age
in the area of the lumbar spine (PA). There was a nega-
tive correlation with age in the neck of the hip and the
Ward’s. BMD correlated negatively with the duration of
HD only in the measurement sites in the forearm. BMI
and BMD were in a positive correlation in the area of the
forearm and the hip (intertrochanter and total hip).
There was no correlation between PTH and BMD at the
site of the lumbar spine, but there was a negative correla-
tion in the area of the hip (trochanter, intertrochanter,
and total hip) and at all sites of the forearm. There was
no statistically significant correlation of BMD with cal-
cium, phosphorus, and the product of calcium and phos-
phorus. Serum ALP was negatively correlated with BMD
at all sites, except in the area of the neck and the Ward’s
(Table 3).
In females there was positive correlation between
BMD and age in the area of the lumbar spine (LL).
There was a negative correlation with age in the area
of the hip (neck and the Ward’s) and in all measure-
ment sites of the forearm. The duration of dialysis was
in a negative correlation at all sites except in the area
of the lumbar spine (LL). There was positive correla-
tion between BMD and BMI in the areas of the lum-
bar spine (AP and LL) and the hip (neck, trochanter,
intertrochanter, total, and the Ward’s); however, there
was no correlation of BMI and forearm BMD. Serum
PTH was negatively correlated with BMD at all sites,
except at the Ward’s triangle and the lumbar spine LL.
There was no significant correlation with calcium and
the product of calcium and phosphorus. ALP was neg-
atively correlated to BMD in all measurement points
(Table 4).
TABLE 1. Demographics, clinical, and laboratory parameters
of the study group.
Variable Mean ± SD Range
Male (N = 72)
Age (years) 56.2 ± 12.6 33–83
Dialysis duration (months) 49.7 ± 61 6–300
BMI (kg/m2) 25.4 ± 3.3 21–34
iPTH (pmol/L) 57.3 ± 59.6* 5–263
Calcium (mmol/L) 2.3 ± 0.2 2.0–2.5
Phosphate (mmol/L) 1.8 ± 0.4 1.0–2.8
Calcium phosphate 
product (mmol2/L2)
4.1 ± 1.0 3.0–6.7
ALP (U/L) 83.4 ± 40.7† 50–325
Female (N = 62)
Age (years) 56.7 ± 11.8 32–83
Dialysis duration (months) 59.5 ± 60.1 6–250
BMI (kg/m2) 25.0 ± 4.8 17–35
iPTH (pmol/L) 79.8 ± 67.9* 3–260
Calcium (mmol/L) 2.3 ± 0.2 2.0–2.6
Phosphate (mmol/L) 1.8 ± 0.4 1.1–2.8
Calcium phosphate 
product (mmol2/L2)
4.5 ± 2.1 3.0–6.7
ALP (U/L) 116.9 ± 108† 52–850
Notes: BMI, body mass index; iPTH, intact parathyroid hor-
mone; ALP, alkaline phosphatase.
*p = 0.02; †p = 0.02.
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TABLE 2. Mean BMD, T-score, and Z-score in female and male patients.
Female (N = 62) Male (N = 72) p
Lumbar spine
PA (total)
BMD (g/cm2) 0.866 ± 0.158 1.011 ± 0.182
T-score −1.6 ± 1.4 −0.7 ± 1.7 0.001
Z-score −0.4 ± 1.5 −0.2 ± 1.7 NS
LL (total)
BMD(g/cm2) 0.587 ± 0.116 0.799 ± 0.195
T-score −3.1 ± 1.3 –
Z-score −0.6 ± 1.3 –
Hip
Neck
BMD(g/cm2) 0.679 ± 0.130 0.808 ± 0.125
T-score −1.5 ± 1.2 −0.9 ± 1.0 0.001
Z-score −0.4 ± 1.1 −0.1 ± 0.9 0.00007
Troch
BMD (g/cm2) 0.547 ± 0.106 0.692 ± 0.116
T-score −1.5 ± 1.0 −0.6 ± 0.9 <0.00001
Z-score −0.7 ± 1.0 −0.3 ± 0.9 <0.00001
Inter
BMD (g/cm2) 0.893 ± 0.167 1.088 ± 0.163
T-score −1.3 ± 1.09 −0.6 ± 0.9 <0.00001
Z-score −0.7 ± 1.2 −0.2 ± 0.9 <0.00001
Total
BMD (g/cm2) 0.757 ± 0.136 0.941 ± 0.138
T-score −1.4 ± 1.2 −0.6 ± 0.9 <0.00001
Z-score −0.6 ± 1.1 −0.3 ± 0.9 <0.00001
Ward’s
BMD (g/cm2) 0.490 ± 0.154 0.597 ± 0.174
T-score −2.1 ± 1.3 −1.3 ± 1.2 0.04
Z-score −0.3 ± 1.3 −0.1 ± 1.2 0.002
Forearm
UD
BMD (g/cm2) 0.311 ± 0.081 0.425 ± 0.097
T-score −2.0 ± 1.6 −1.6 ± 1.4 NS
Z-score −1.0 ± 1.5 −0.9 ± 1.5 NS
MID
BMD(g/cm2) 0.466 ± 0.100 0.613 ± 0.092
T-score −2.3 ± 1.9 −1.4 ± 1.7 0.01
Z-score −0.9 ± 1.7 −0.8 ± 1.7 NS
One-third
BMD(g/cm2) 0.571 ± 0.113 0.745 ± 0.091
T-score −1.9 ± 1.9 −1.3 ± 1.5 NS
Z-score −0.6 ± 1.8 −0.5 ± 1.6 NS
Total
BMD(g/cm2) 0.451 ± 0.096 0.600 ± 0.086
T-score −2.0 ± 2.1 −1.5 ± 1.6 NS
Z-score −0.9 ± 1.7 −0.7 ± 1.6 NS
Notes: BMD, bone mineral density; PA, posterior–anterior; LL, lateral–lateral; Troch, trochanter; Inter, inter-
trochanter; Ward’s, Ward’s Triangle; UD, ultradistal; MID, middistal; 1/3, one-third; NS, not significant.
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Correlations of BMD among different sites are
given in Tables 5 and 6. Correlation ranged from
0.100 to 0.991 among different sites in males and from
0.319 to 0.993 in females. The best correlation for
males and females was between MID forearm and the
total hip and the intertrochanter (r = 0.769 and 0.761
in females; r = 0.534 and 0.537 in males). We found
better correlation between axial and appendicular skel-
etal sites in females than in males.
Osteoporosis
The prevalence of osteoporosis in males, according to
ISCD recommendations (T-score < −2.5), was 10% in
lumbar spine AP projection and 3% in hip neck. At
other sites, the prevalence of a T-score < −2.5 was
between 0 and 29%. In the same group, the prevalence
of low bone mass (T-score between −1.0 and −2.5)
was between 33 and 49% (Table 7).
In female patients, the prevalence of osteoporosis
based on the same criteria was 31% in lumbar spine
AP projection, 18% in hip neck, and 18% in total hip.
At other sites, the T-score < −2.5 was between 16%
and up to 68% in LL lumbar spine. The prevalence of
low bone mass was between 26% and up to 55% in the
hip neck (Table 7).
According to the Z-score, the prevalence of low
bone density (Z-score<−1) in male patients was
between 15 and 50% and the Z-score below the
TABLE 3. Correlation between BMD of measurement sites laboratory and clinical parameters, expressed as a coefficient of correlation (r)
in male patients.
Lumbar spine Hip Forearm
PA total LL total Neck Troch Inter Total Ward’s UD MID 1/3 Total
Age 0.300* NS −0.293† NS NS NS −0.314* NS NS NS NS
HD NS NS NS NS NS NS NS −0.295† −0.390‡ −0.351* −0.388‡
BMI NS NS NS NS 0.322* 0.294† NS 0.279† 0.284† NS 0.271†
iPTH NS NS NS −0.277† −0.263† −0.280† NS −0.286† −0.340* −0.306* −0.346*
Ca NS NS NS NS NS NS NS NS NS NS NS
P NS NS NS NS NS NS NS NS NS NS NS
Ca × P NS NS NS NS NS NS NS NS NS NS NS
ALP −0.254† −0.281† NS −0.261† −0.248† −0.256† NS −0.232† −0.385‡ −0.377‡ −0.378‡
Notes: BMD, bone mineral density; PA, posterior–anterior; LL, lateral–lateral; Troch, trochanter; Inter, intertrochanter; Ward’s,
Ward’s Triangle; UD, ultradistal; MID, middistal; 1/3, one-third; BMI, body mass index; iPTH, intact parathyroid hormone; Ca,
calcium; P, phosphorus; ALP, alkaline phosphatase; NS, not significant.
*p < 0.01; †p < 0.05; ‡p < 0.001; (r = 0.302, p < 0.01), (r = 0.232, p < 0.05), (r = 0.372, p < 0.001).
TABLE 4. Correlation between PTH and BMD in measurement sites expressed as a coefficient of correlation (r) in female patients.
Lumbar spine Hip Forearm
PA total LL total Neck Troch Inter Total Ward’s UD MID 1/3 Total
Age NS 0.273* −0.277* NS NS NS −0.366† −0.326† −0.381† −0.384† −0.380†
HD −0.453‡ NS −0.436‡ −0.315* −0.356† −0.384† −0.280* −0.394† −0.426‡ −0.422‡ −0.425‡
BMI 0.328† 0.328† 0.406‡ 0.356† 0.383† 0.421‡ 0.310* NS NS NS NS
iPTH −0.384† NS −0.369† −0.359† −0.390† −0.400‡ NS −0.342† −0.414‡ −0.371† −0.398‡
Ca NS NS NS NS NS NS NS NS NS NS NS
P 0.272* NS NS 0.300 NS NS NS NS NS NS NS
Ca × P NS NS NS NS NS NS NS NS NS NS NS
ALP −0.360† −0.274* −0.463‡ −0.480‡ −0.508‡ −0.527‡ −0.385† −0.349† −0.349† −0.375† −0.331†
Notes: PA, posterior–anterior; LL, lateral–lateral; Troch, trochanter; Inter, intertrochanter; Ward’s, Ward’s Triangle; UD, ultradis-
tal; MID, middistal; 1/3, one-third; BMI, body mass index; iPTH, intact parathyroid hormone; Ca, calcium; P, phosphorus; ALP,
alkaline phosphatase; NS, not significant.
*p < 0.05; †p < 0.01; ‡p < 0.001; (r = 0.250, p < 0.05), (r = 0.325, p < 0.01), (r = 0.395, p < 0.001).
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expected range for age (Z-score < −2.0) was between 5
and 22% (Table 8). In female patients, the prevalence
of low bone mass density according to the Z-score was
23% at the Ward’s, up to 56% at UD forearm, and the
prevalence of Z-score below the expected range for age
was between 5 and 26% (Table 8).
DISCUSSION
In our study, a significant percentage of patients on
HD had significantly decreased BMD as assessed by
T- or Z-score. The reduced T- or Z-score was not the
same on all measured skeletal sites and there was also
a difference between genders. The prevalence of
osteoporosis, defined as a T-score < 2.5 at peripheral
skeletal sites (forearm), was up to 35% in females and
29% in males. At the central part of skeleton, the prev-
alence was 20% in males at the Ward’s Triangle and
more than 68% in LL lumbar spine in females.
Reduced bone mass, that is, a T-score between −1 and
−2.5, was detected in more patients, but the difference
in prevalence between skeletal sites was less pro-
nounced.
There are suggestions that the Z-score should be
used in evaluating bone density in CKD patients. The
ISCD has recommended that the Z-score should be
expressed as Z-score of −2.0 or lower and defined as
TABLE 5. Correlation between BMD of individual measurement sites expressed as a coefficient of correlation (r) in female patients.
PA total LL total Neck Troch Inter Total Ward’s UD MID 1/3 Total
PA 1 0.571 0.687 0.709 0.722 0.752 0.620 0.643 0.581 0.568 0.610
LL 0.571 1 0.458 0.513 0.413 0.466 0.413 0.392 0.374 0.319 0.373
Neck 0.687 0.458 1 0.737 0.871 0.911 0.842 0.716 0.740 0.717 0.750
Troch 0.709 0.513 0.737 1 0.799 0.872 0.698 0.700 0.635 0.584 0.653
Inter 0.722 0.413 0.871 0. 799 1 0.980 0.794 0.749 0.769 0.739 0.778
Total 0.752 0.466 0.911 0.872 0.980 1 0.805 0.763 0.761 0.727 0.773
Ward’s 0.620 0.413 0.842 0.698 0.794 0.805 1 0.618 0.598 0.581 0.616
UD 0.643 0.392 0.716 0.700 0.749 0.763 0.618 1 0.865 0.792 0.905
MID 0.581 0.374 0.740 0.635 0.769 0.761 0.598 0.865 1 0.792 0.993
1/3 0.568 0.319 0.717 0.584 0.739 0.727 0.581 0.792 0.792 1 0.963
Total 0.610 0.373 0.750 0.653 0.778 0.773 0.616 0.905 0.993 0.963 1
Notes: BMD, bone mineral density; PA, posterior–anterior; LL, lateral–lateral; Troch, trochanter; Inter, intertrochanter; Ward’s,
Ward’s Triangle; UD, ultradistal; MID, middistal; 1/3, one-third.
TABLE 6. Correlation between BMD of individual measurement sites expressed as a coefficient of correlation (r) in male patients.
PA LL Neck Troch Inter Total Ward’s UD MID 1/3 Total
PA 1 0.659 0.298 0.559 0. 449 0.480 0.211 0.371 0.311 0.289 0.358
LL 0.659 1 0.416 0.529 0.470 0.513 0.361 0.435 0.353 0.261 0.394
Neck 0.298 0.416 1 0.633 0.727 0.795 0.821 0.286 0.281 0.194 0.287
Troch 0.559 0.529 0.633 1 0.800 0.873 0.460 0.478 0.443 0.331 0.466
Inter 0.449 0.470 0.727 0.800 1 0.976 0.555 0.512 0.534 0.345 0.540
Total 0.480 0.513 0.795 0.873 0.976 1 0.621 0.527 0.537 0.365 0.548
Ward’s 0.211 0.361 0.821 0.460 0.555 0.621 1 0.184 0.152 0.100 0.153
UD 0.371 0.435 0.286 0.478 0.512 0.527 0.184 1 0.758 0.394 0.802
MID 0.311 0.353 0.281 0.443 0.534 0.537 0.152 0.758 1 0.842 0.991
1/3 0.289 0.261 0.194 0.331 0.345 0.365 0.100 0.394 0.842 1 0.838
Total 0.358 0.394 0.287 0.466 0.540 0.548 0.153 0.802 0.991 0.839 1
Notes: BMD, bone mineral density; PA, posterior–anterior; LL, lateral–lateral; Troch, trochanter; Inter, intertrochanter; Ward’s,
Ward’s Triangle; UD, ultradistal; MID, middistal; 1/3, one-third.
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“below the expected range for age” and a Z-score
above −2.0 is “within the expected range for age.”4 On
the contrary, nephrologists in the Osteoporosis Work
Group suggested that in CKD patients low bone
density could be defined as a Z-score of −1.0 or less.10
Therefore, we used both criteria. Low bone density,
that is, a Z-score < −1, depending on the skeletal site,
was detected in up to 50% of male patients and 56%
TABLE 7. Osteoporosis and reduced bone mass compared to
T-score.
Normal 
N (%)
Reduced bone 
mass N (%)
Osteoporosis 
N (%)
Lumbar spine
PA
Male 38 (53) 24 (33) 10 (14)
Female 22 (35) 21 (34) 19 (31)
LL
Male – – –
Female 4 (6) 16 (26) 42 (68)
Hip
Neck
Male 36 (50) 34 (47) 2 (3)
Female 17 (27) 34 (55) 11 (18)
Troch
Male 43 (60) 29 (40) 0 (0)
Female 16 (26) 34 (55) 12 (19)
Inter
Male 43 (60) 28 (39) 1 (1)
Female 24 (39) 28 (45) 10 (16)
Total
Male 43 (60) 29 (40) 0 (0)
Female 20 (32) 31 (50) 11 (18)
Ward’s
Male 22 (30) 35 (49) 15 (21)
Female 9 (14) 29 (47) 24 (39)
Forearm
UD
Male 22 (30) 30 (42) 20 (28)
Female 16 (26) 25 (40) 21 (34)
MID
Male 26 (36) 25 (35) 21 (29)
Female 13 (21) 27 (44) 22 (35)
1/3
Male 30 (42) 27 (37) 15 (21)
Female 18 (29) 25 (40) 19 (31)
Total
Male 26 (36) 27 (37) 19 (26)
Female 16 (26) 24 (39) 22 (35)
Notes: PA, posterior–anterior; LL, lateral–lateral; Troch,
trochanter; Inter, intertrochanter; Ward’s, Ward’s Triangle; UD,
ultradistal; MID, middistal; 1/3, one-third.
TABLE 8. Z-score in female and male patients.
Z < −1 N (%) Z < −2 N (%)
Lumbar spine
PA
Male 28 (39) 8 (11)
Female 18 (29) 5 (8)
LL
Male – –
Female 26 (42) 6 (10)
Hip
Neck
Male 12 (17) 3 (5)
Female 20 (32) 3 (5)
Troch
Male 24 (33) 4 (6)
Female 27 (43) 6 (10)
Inter
Male 16 (22) 3 (5)
Female 21 (34) 6 (10)
Total
Male 13 (18) 3 (5)
Female 19 (31) 6 (10)
Ward’s
Male 11 (15) 3 (5)
Female 14 (23) 4 (6)
Forearm
UD
Male 35 (49) 15 (21)
Female 35 (56) 16 (26)
MID
Male 36 (50) 16 (22)
Female 28 (45) 14 (23)
1/3
Male 28 (39) 13 (18)
Female 25 (40) 12 (19)
Total
Male 35 (49) 13 (18)
Female 27 (43) 14 (23)
Notes: PA, posterior–anterior; LL, lateral–lateral; Troch,
trochanter; Inter, intertrochanter; Ward’s, Ward’s Triangle;
UD, ultradistal; MID, middistal; 1/3, one-third.
Z < −1, low bone density, Z < −2 bellow the expected range for
age.
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of female patients. Interestingly, the prevalence was
higher at peripheral skeletal sites. The prevalence of a
Z-score < −2.0, below the expected range for age, was
less than 11% in all central skeletal sites in females and
males and much higher at the peripheral skeletal sites.
In both groups, the prevalence of a Z-score below the
expected for age range at the peripheral skeletal sites
was between 18 and 26%. This is indisputable because
the criteria that we are using and the sites that we are
measuring significantly influence osteoporosis or low
bone mass.
It is well known that there is a correlation between
BMD measurements made in the same patient at
different skeletal sites. It varies between r = 0.4 and
r = 0.9.5,11 In our patients the correlation between
BMD at different skeletal sites varied between r = 0.1
and r = 0.99. There was a difference in correlation
between different skeletal sites in females and males.
Generally, a better correlation between different
skeletal sites was observed in female patients.
Age, gender, hormonal factors, BMI, and PTH
level are risk factors for osteoporosis, that is, reduced
bone mass.12 There are some other risk factors in
dialysis patients, for example, the length of time on
dialysis. In our patients there was a negative correla-
tion between the length of time on HD treatment
and bone density at the forearm in males and
females but at the central part of skeleton only in
females. In males there was no correlation between
age and forearm bone mass, and in female patients
there was a negative correlation between age and
forearm bone mass.
As expected, a negative correlation was observed
between PTH level and BMD. In female patients, the
correlation at peripheral and central skeletal sites was
better than in males. In addition, PTH and most prob-
ably other hormonal deficiencies, that is, the defi-
ciency of estrogen, have an added effect on the loss of
bone mass at the lumbar spine in females.
Renal bone disease, as one CKD–mineral bone dis-
order (MBD), is caused by a combination of several
metabolic disorders resulting from chronic kidney
insufficiency.6,9 The most important ones are phos-
phate reduction, serum calcium disorder, deficiency of
vitamin D, and increased PTH level.13 In some CKD
patients, particularly diabetics and older patients, low
levels of PTH could be found. Low bone turnover is a
histological picture of low PTH level in CKD patients.
In patients with a high PTH level, the characteristic
histological picture of bone is high turnover.6,8 In both
types of bone changes in CKD patients that is, high or
low bone turnover normal bone density could be
found.8,10,12,14 There is one more important point in
CKD–MBD – the high incidence of pathological
calcifications, particularly vascular calcification. The
incidence of calcification is similar in patients with low
and high turnover bone disease.8,9
The prevalence of low bone mass and bone frac-
tures is high among CKD patients. In some studies,
the prevalence of low bone mass, that is, osteoporosis
was up to 80% at the mid-radius, 47% at the hip neck,
a bit less at lumbar spine, and less than 30% and
around 50% at the total body.12,15–17 In many studies,
a different prevalence was observed and even a differ-
ence between HD and peritoneal dialysis was
observed.16–19 There is also much data showing that
the fracture risk in CKD patients is very high, more
than 4 times higher than in the general population.4,20
The goal of our study was not to investigate the preva-
lence of bone fractures. However, we did observe only
three patients with fractures. Most probably we would
have found a greater number of pathological fractures if
we had used another method, such as X-ray of the spine.
However, bone densitometry is a good method in evalu-
ating bone density in the general population and the
results, that is, BMD or T-score, are strong predictors of
fracture risk. Unfortunately, this is not so with CKD
patients. There are many reasons for this. First, bone
quality in CKD is severely affected not only by aging (as
is most often the case in the general population), but
also by a severe disarrangement of mineral metabo-
lism.1,6,12 Bone density (assessed by one of the densito-
metric methods) is only one part of bone quality in
CKD patients. Bone turnover is the second important
part, although the “gold standard” in assessing bone
turnover is an invasive method, that is, bone biopsy.10
DXA is the “gold” standard in the diagnosis of
bone loss in the general population.1,3 Central skeletal
sites are the most important. BMD, expressed as a
T-score, should be used in evaluating osteoporosis.4
From our study and others, it is clear that DXA results
should not be interpreted so simply in CKD patients.
There are many reasons for this. In patients with high
turnover bone disease resulting from secondary hyper-
parathyroidism, changes on peripheral skeletal sites
which mean more cortical bone, for example, up to 95
at the distal third of radius, are more pronounced.8
DXA of central skeletal sites, that is, the lumbar spine,
has some technical limitations in CKD patients.11,21 A
high incidence of aortic calcifications and the endplate
osteosclerosis of vertebral bodies could have an impact
on DXA results. The forearm thus seems to be a
promising site. The ISCD has suggested that DXA
scans should be performed in the distal third of the
radius in patients with hyperparathyroidism. The
problem is that this is valuable for patients with pri-
mary hyperparathyroidism, whereas bone changes in
secondary hyperparathyroidism are a bit different.4
Unfortunately, it is not possible to distinguish trabecu-
lar and cortical bone with DXA.
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Therefore, at present DXA scans at more sites
should be recommended for patients with CKD–MBD,
including appendicular, for example, distal forearm, but
also at the central part of the skeleton. Finally, the ques-
tion is whether to use the T-score or the Z-score. The
T-score is useful only in Caucasian females. At present,
we do not know what Z-score value should be used in
distinguishing CKD patients with low bone mass.
In our study, we tried to determine the optimal site
of bone mass measurement in CKD patients. There
are some limitations in this study. Most important, it is
a cross-sectional study with a relatively small number
of patients and the use of only one method (DXA).
Regardless of these limitations, we have shown that
there is reduced bone mass in HD patients, that there
is a different reduction between skeletal sites and
between genders, and also that there is a difference if
the results are expressed as a T-score or a Z-score.
Undoubtedly, more long-term studies with DXA and
other methods, for example, peripheral quantitative
computed tomography (pQCT), are required.21
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